We have updated our Privacy Policy. Please review our Privacy Policy. This website uses cookies. By using our website without changing your cookie settings, you agree to our use of cookies as described in our Privacy Policy.

Close
VIVITROL is a prescription injectable medicine used to:
  • Treat alcohol dependence. You should stop drinking before starting VIVITROL.
  • Prevent relapse to opioid dependence, after opioid detoxification.

You must stop taking opioids before you start receiving VIVITROL. To be effective, VIVITROL must be used with other alcohol or drug recovery programs such as counseling.

VIVITROL may not work for everyone. It is not known if VIVITROL is safe and effective in children.

ONCE-MONTHLY VIVITROL ALONG WITH COUNSELING MAY GIVE YOU A PATH FORWARD IN YOUR OPIOID DEPENDENCE RECOVERY JOURNEY1

Continually facing the consequences of opioid dependence can be a challenge, but you are not alone.

VIVITROL and counseling may be able to help.

VIVITROL and counseling have been proven to prevent relapse to opioid dependence after opioid detox1-3

In a 6-month study of patients with opioid dependence who completed opioid detoxification, 36% of patients who received VIVITROL and counseling were opioid-free at all weekly visits* versus 23% of patients who received placebo (injection without medication) and counseling.

*Opioid-free was defined as a negative urine drug test for opioids and no self-reported opioid use. Data were not collected during Weeks 1-4 of the clinical trial to allow for stabilization of abstinence.3 Patients received individual drug counseling every other week.2

Patient self-reported opioid craving2,3

In the same study, craving information was reported by patients each week. When comparing average craving scores at the beginning and the end of the study, craving in the VIVITROL group went down 10.1 points, while craving in the placebo group went up 0.7 points.

Craving was described as a "need for opioids" and self-measured by patients each week on a scale from 0 to 100, with 0 being "none" and 100 being "very much so."

Common side effects of VIVITROL in clinical studies included nausea, sleepiness, headache, dizziness, vomiting, decreased appetite, painful joints, muscle cramps, cold symptoms, trouble sleeping, and toothache.

Please see Important Safety Information.

VIVITROL is a once-monthly injection

Your recovery journey is worth fighting for.

ASK YOUR HEALTHCARE PROVIDER IF
ONCE-MONTHLY VIVITROL MAY BE RIGHT FOR YOU.


If you're struggling with Opioid dependence, you're not alone.

While everyone's struggle with opioid dependence is different, it can be encouraging to hear stories from others in similar situations. Meet Christina and learn about her recovery journey from opioid dependence.

Patient stories reflect individual experiences.
Individual experiences may vary.
See Christina's story

NEED HELP PREPARING FOR TREATMENT?

These tips may help you prepare for your VIVITROL injection.

Learn more

VIVITROL is not right for everyone. There are significant risks from VIVITROL treatment, including risk of opioid overdose, severe reactions at the injection site, sudden opioid withdrawal, liver damage or hepatitis.

Talk to your healthcare provider about naloxone, a medicine that is available to patients for the emergency treatment of an opioid overdose.

Call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if naloxone is administered.

If you are being treated for alcohol dependence but also use or are addicted to opioid-containing medicines or opioid street drugs, it is important that you tell your healthcare provider before starting VIVITROL to avoid having sudden opioid withdrawal symptoms when you start VIVITROL treatment.

See Important Safety Information.

See Prescribing Information and Medication Guide.


References: 1. VIVITROL [prescribing information]. Waltham, MA: Alkermes, Inc. 2. Data on file. Alkermes, Inc. Waltham, MA. 3. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-1513.

References: 1. VIVITROL [prescribing information]. Waltham, MA: Alkermes, Inc. 2. Data on file. Alkermes, Inc. Waltham, MA. 3. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-1513.

We have updated our Privacy Policy. Please review our Privacy Policy. This website uses cookies. By using our website without changing your cookie settings, you agree to our use of cookies as described in our Privacy Policy.

Close